Opus Genetics, Inc. (IRD): Other Ashwath Jayagopal mutual agreement

Events in this filing

Item 5.02 as filed

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Opus Genetics, Inc. (the “Company”) and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the
Company’s Chief Scientific and Development Officer, effective as of October 19, 2026 (the “Separation Date”).
Effective on the Separation Date, the Company entered into a separation and release agreement with Dr. Jayagopal, which includes a
consulting agreement (together, the “Letter Agreement”), which provides for a six-month consulting arrangement pursuant to which Dr. Jayagopal will provide transition services to the Company, as requested by the Company. Dr. Jayagopal will be
compensated for such services at a rate of $250 per hour. Dr. Jayagopal’s outstanding vested options as of the Separation Date will remain exercisable during the term of the consulting arrangement.
The foregoing description of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to
the text of the Letter Agreement (including the consulting agreement attached as Exhibit A thereto), a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2026.